Bevacizumab (intra-ocular)

OFFICE ADMINISTRATION: Sterile environment / Aseptic technique

Indications for Prior Authorization:

  • Neovascular (WET) age related Macular Degeneration (AMD)
  • Macular retinal edema
  • Diabetic macular edema
  • Cystoid macular degeneration
  • Rubeosis iridis
  • Choroidal neovascularization, one or more of the following:
  • Angioid streaks
  • Choroiditis
  • Degenerative myopia
  • Retinal dystrophies
  • Neovascular glaucoma
  • Retinal vein occlusion (branch or central)

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Any other diagnosis not listed in the approved indications

Dosing:

  • Up to 2.5mg every 4 weeks by intravitreal injection

Monitoring:

  • Elevation in intraocular pressure ocular inflammation (endophthalmitis) immediately after injection check for perfusion of the optic nerve head measure intraocular pressure (tonometry) within 30 minutes following injection slit lamp biomicroscopy between 2 and 7 days following injection

 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.